DGAP-News: Marizyme, Inc. / Key word(s): Miscellaneous
Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting
JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizyme announced that results from its European DuraGraft Registry were presented on October 8, 2020 at the EACTS Annual Meeting.
The EACTS Conference is the largest cardio-thoracic and vascular surgery meeting in the world focusing on scientific developments and research. This highly recognized and respected meeting held virtually this year from Barcelona, Spain, is the ideal platform to bring scientific developments to the forefront, providing a stage to present solid research on new technologies such as DuraGraft.
The presentation by Dr. Maximilian Emmert (German Heart Center in Berlin, Germany, lead Principal Investigator and Chair of the advisory committee for the European CABG registry) entitled "Clinical event rate in patients with and without left main disease undergoing CABG: results from the prospective European DuraGraft Registry," highlighted the results of a clinical registry focused on enhanced outcomes for coronary artery bypass grafting (CABG) in patients treated with DuraGraft, an intra-operative graft storage solution. This 3,000 patient open enrollment (clinicaltrials.gov: NCT02922088) VASC trial in 45 major cardiovascular centers around Europe, in patients who have undergone CABG, shows low myocardial infarction and repeat revascularization rates at 30 days and 1-year post CABG. The registry provides detailed real-world insights into clinical outcomes associated with CABG with DuraGraft in patients with and without left main coronary artery disease (LMCAD) and emphasizes the importance of intraoperative graft preservation in conjunction with CABG.
"We are very excited to have been selected to present our findings during an oral presentation and share the first results from this ongoing large European clinical registry with our colleagues from around the globe at this year's EACTS conference," said Dr. Emmert.
Dr. Satish Chandran, President of Marizyme stated, "Clinical evidence generated by independent researchers around the world has provided important insight into risk factors and outcomes of contemporary patients undergoing CABG. The European DuraGraft Registry shows improvement over literature derived outcomes and demonstrates the value proposition of DuraGraft to patients, cardiac centers, and healthcare systems worldwide. We at Marizyme are extremely excited to offer this product to CABG patients."
About CABG and DuraGraft
DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. DuraGraft protects graft tissue from harvesting through anastomosis and is used during vascular surgery (including CABG) as a treatment to maintain the structural and functional integrity of isolated vascular grafts. The use of DuraGraft is associated with the reduction of post-CABG complications associated with graft disease and failure: myocardial infarction, repeat revascularization, and MACE (a composite of all major adverse cardiac events).
Clinical studies in more than 3,000 patients support the long-term safety and efficacy of DuraGraft compared to unproven standard of care solutions which are not approved or labeled for this use case. The use of DuraGraft in CABG surgery is associated with statistically significant lower risks for clinical complications following CABG; 45% reduction in non-fatal myocardial infarction (MI) (p <.0001), 35% reduction in repeat revascularization (p=0.037), and 19% reduction of MACE (p=0.005) (Haime et al. 2018).
About Marizyme, Inc.
For more information about Marizyme, visit www.marizyme.com.
SOURCE: Marizyme, Inc.
12.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.